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ABSTRACT.
Purpose: To determine change in visual acuity (VA) in the population of a
previous amblyopia treatment study (Loudon 2006) and assess risk factors for
VA decrease.
Methods: Subjects treated between 2001 and 2003 were contacted between
December 2015 and July 2017. Orthoptic examination was conducted under
controlled circumstances and included subjective refraction, best corrected VA,
reading acuity, binocular vision, retinal fixation, cover-uncover and alternating cover
test. As ameasure for degree of amblyopia, InterOcular VADifference (IOD) at the
end of occlusion therapywas comparedwith IODat the follow-up examination using
Wilcoxon’s signed-rank test. Regression analysis was conducted to determine the
influence of clinical and socio-economic factors on changes in IOD.
Results: Out of 303 subjects from the original study, 208 were contacted
successfully, 59 refused and 15 were excluded because of non-amblyopic cause of
visual impairment. Mean IOD at end of therapy (mean age 6.4 years) was
0.11  0.16 logMAR, and IOD at follow-up examination (mean age 18.3 years)
was 0.09  0.21 logMAR; this difference was not significant (p = 0.054). Degree
of anisometropia (p = 0.008; univariable analysis), increasing anisometropia
(p = 0.009; multivariable), eccentric fixation (p < 0.001; univariable and multi-
variable); large IOD (p < 0.001; univariable and multivariable) and non-compli-
ance during therapy (p = 0.028; univariable) were associated with IOD increase.
Conclusion: Long-term results of occlusion therapy were good. High or
increasing anisometropia, eccentric fixation and non-compliance during occlu-
sion therapy were associated with long-term VA decrease. Subjects with poor
initial VA had a larger increase despite little patching, but often showed long-
term VA decrease.
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Introduction
Amblyopia is the most common cause
of monocular visual acuity loss in
children with a prevalence varying
from 1.6% to 3.5% (Reeves 2002). It
is mainly caused by strabismus and/or
anisometropia or visual deprivation,
which disrupts the equal input from
both eyes to the visual cortex. Standard
therapy is spectacle correction if neces-
sary, and occlusion of the fellow eye
several hours per day during the sensi-
tive period (Stewart et al. 2004a,b).
Occlusion therapy is a very success-
ful treatment; however, its success is
hampered by non-compliance (Loudon
et al. 2003; Stewart et al. 2004a;
Loudon et al. 2006; Stewart et al.
2007). Long-term results of occlusion
therapy vary widely (Leiba et al. 2001;
Holmes et al. 2004; Rutstein & Corliss
2004; Repka et al. 2005; Scott et al.
2005; Bhola et al. 2006; Hertle et al.
2007; Simonsz-Toth et al. 2007; Pedi-
atric Eye Disease Investigator Group
et al. 2008; Saxena et al. 2013). Visual
acuity deteriorated in 7–75% of the
cases, largely depending on duration of
follow-up and definition of outcome
(Rutstein & Fuhr 1992; Hertle et al.
2007). Reported factors that negatively
influenced the course of visual acuity
after cessation of therapy included
poor visual acuity at start of treatment,
combined cause of amblyopia, eccen-
tric fixation and age (Levartovsky et al.
1995; Bhola et al. 2006; Simonsz-Toth
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et al. 2007). Almost all long-term
studies were done retrospectively. Per-
sistent amblyopia causes a significant
burden on society, financially as well as
a reduced quality of life (van de Graaf
et al. 2007). It also nearly doubles the
time an individual spends with bilateral
visual impairment due to loss of vision
in the non-amblyopic eye: this increases
from 8 to 15.5 months, on average (van
Leeuwen et al. 2007).
In our previous randomized controlled
trial (RCT; 2001–2003, N = 303,
NCT00131729), all newly diagnosed
amblyopic children in four clinics in The
Hague were registered. Included children
received occlusion therapy, while compli-
ance was measured electronically using
the occlusion dose monitor (ODM). The
purpose of the study was to determine
whether compliance could be improved
using an educational cartoon programme
aimed at the child, and to identify risk
factors for non-compliance. We found
predictors for non-compliance to be a low
initial visual acuity, poor parental fluency
in the national language and low parental
level of education. The educational pro-
gramme significantly improved compli-
ance throughout the study, limiting in
particular the number of children who
were not occluded at all. (Loudon et al.
2006).
The purpose of this study was to
determine the long-term course of the
visual acuity after cessation of occlusion
therapy for amblyopia and identify
those at risk for visual acuity deteriora-
tion. At the time of this follow-up
measurement, all children were adoles-
cents, most of them still living with their
parents. They were contacted again for
examination of their current visual acu-
ity. Both the visual acuitymeasurements
at the end of occlusion therapy and at
the follow-up examination were per-
formed under the same strictly con-
trolled conditions by the same research
orthoptist (BST). Compliance during
occlusion therapy had been measured
electronically, and detailed clinical and
socio-demographic data were readily
available of all subjects.
Materials and Methods
Study population and orthoptic
examination in amblyopia treatment
study 2001–2004
Subjects were derived from a previous
RCT, in which all newly diagnosed
amblyopic children had been recruited
from the four clinics in The Hague from
2001 until 2003 (Loudon et al. 2006).
The design for this prospective study has
been reported in detail elsewhere (Lou-
don et al. 2006). Briefly, all amblyopic
children were given standard orthoptic
care with routine assessment every 3–
4 months by the treating orthoptist. All
measurements were conducted under
controlled circumstances. Duration of
occlusion (number of hours per day) for
the first prescription was standardized
according to the following formula:
6.63 9 ratio acuity amblyopic eye/
acuity better eye + 0.5 9 age
(years) + 4.97. Compliance was mea-
sured electronically using the ODM.
Children were randomized to either the
intervention group or the control group.
The intervention group received an
educational programme explaining to
the child without words the reasons for
patching. The control group received a
picture to colour, without an educa-
tional message. The family’s socio-eco-
nomic status was ascertained using a 23-
item questionnaire.
Occlusion therapy was completed
when the interocular difference in
visual acuity was one logMAR line or
less on two consecutive visits to the
orthoptist. From 2004 the research
orthoptist assessed best corrected
visual acuity with the Landolt-C chart
17.2’ in children whose occlusion treat-
ment was either ‘completed’ by the
orthoptists or ‘terminated’ by the par-
ents (i.e. parents who failed to attend
the appointments in clinic). The
research orthoptist tested the best cor-
rected visual acuity with the Landolt-C
chart 17.2’ minutes of distance between
optotypes at 5m distance. At least 3 out
of 5 optotypes had to be answered
correctly per line. The luminance of the
chart was measured during the tests.
This ranged from 160 to 320 cd/m2,
which is in accordance with the ISO-
8596 Standard.
Follow-up examination 2015–2017
All orthoptic and demographic data
from the original 303 files were readily
available and analysed. From these
files, last known contact information
was obtained. The subjects were con-
tacted from December 2015 until July
2017 (Fig. 1). Eighty-nine (29%) could
not be contacted using the available
information from the original trial and
six subjects had moved abroad. We
were able to contact 208 subjects
(69%), of whom 59 (19%) refused
participation with a follow-up exami-
nation. Reasons for refusing participa-
tion included time or interest issues
(N = 33), not showing up for the
appointment on multiple occasions
(N = 20), no eye complaints (N = 3)
or had recently visited the ophthalmol-
ogy department or optician (N = 3).
One subject could not be examined due
to other disabilities. In total, 148 sub-
jects were examined, of these 14 were
excluded. Reasons for exclusion were
diminished visual acuity due to other
ocular diseases (e.g. optic neuritis, mild
oculocutaneous albinism) or brain
damage (e.g. haemorrhage). In two
subjects, the visual acuity at the end
of occlusion therapy was unknown and
could not be obtained; in eight sub-
jects, the diagnosis of amblyopia could
not be confirmed, in hindsight.
The Ethical Committee of Erasmus
University Rotterdam and the boards
of the participating clinics approved
the protocol and informed consent
forms. Written informed consent was
obtained from each subject and/or
from his or her parents or guardians.
The research adhered to the tenets of
the Declaration of Helsinki.
The follow-up examinations were
carried out at the outpatient clinic at
HaaglandenMedical Center,Westeinde
The Hague and conducted by the same
research orthoptist (BST) who had
examined the same subjects at the end
of occlusion therapy, using the same
protocol for measurement for visual
acuity as in 2004. Examinations were
performed through domiciliary visits if
the subjects refused to visit the hospital.
Binocular vision was assessed with
Bagolini striated glasses, Titmus-Fly
and TNO-test and expressed in five
categories: (1) Bagolini negative; (2)
Bagolini positive; (3) Bagolini and Tit-
mus-Fly test positive; (4) TNO plate
480”-240”; (5) TNO plate 120”-15”.
Retinal fixation and ocular alignment
were investigated with the cover-un-
cover and alternating cover test at 30cm
and 5m distance. Target for the cover
test for fixation at near was a small
object with detailed pictures to stimu-
late accommodation and to assess fixa-
tion. The target of the cover test at
distance was a penlight. Reading acuity
was tested using the Dutch version of
the Radner Reading Chart (Maaijwee
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et al. 2008). Subjects were examined
with their current spectacles. The best
corrected visual acuity (BCVA) was
determined using the Righton Retino-
max handheld auto (kerato)-refractor
together with subjective refraction in all
subjects. Cycloplegic refraction was
part of the original protocol, but most
of the subjects refused participation if
this was obliged. Therefore, to ensure
for a reliable calculation of the refrac-
tive error, we performed subjective
refraction whereby the accommodation
was eliminated with hypermetropic
lenses. Degree of anisometropia was
determined by calculating the difference
in spherical equivalent between the two
eyes based on the subjective refraction.
Current degree of anisometropia was
compared with the degree of ani-
sometropia as measured with cyclo-
plegic refraction at start of therapy:
[Anisometropia follow-up] – [Ani-
sometropia start of therapy]. Loss of 2
logMAR lines or more in visual acuity
was defined as ‘severe deterioration’.
Statistics
Differences in characteristics, that is
clinical and socio-economic data from
the original study (N = 303), between
subjects who completed the follow-up
examination (N = 134) and those who
did not, were investigated to assess for
potential bias. These differences were
tested using T-tests and Mann–Whit-
ney tests for the following continuous
variables: age at start of therapy, IOD
at start, anisometropia at start, com-
pliance during therapy, IOD at end of
therapy. The chi-square test was used
to investigate the following categorical
variables: eccentric fixation, gender,
randomization group, fluency in the
national language, level of education,
number of working hours per week,
country of origin and home-ownership.
As a measure for the degree of ambly-
opia, we used the InterOcular VA Dif-
ference (IOD). The IOD at the end of
occlusion therapy as measured by the
research orthoptist (BST in 2004) was
compared with the IOD as measured at
the follow-up examination (BST in
2016). The main outcome measure was
this change in IOD after cessation of
occlusion therapy, calculated with the
following formula: [VAae – Vafe]follow-up
examination – [VAae – Vafe]end of occlusion
treatment, with VAae the visual acuity of
the amblyopic eye and VAfe the visual
acuity of the fellow eye (logMAR). The
Wilcoxon signed-rank test was used to
assess any significant changes in IODand
binocular vision between end of occlu-
sion treatment and at the follow-up
examination. The Spearman correlation
was used to determine the association
between visual acuity and reading acuity.
The influence of spectacle wearing on
change in anisometropia was investi-
gated with regression analysis.
In addition, we assessed risk factors
for visual acuity deterioration. Uni-
variable linear regression analysis was
performed to investigate which clinical
(i.e. age, gender, randomization, diag-
nosis, visual acuity, anisometropia,
retinal fixation, compliance, and dura-
tion of occlusion therapy) and socio-
economic variables (i.e. parental flu-
ency in the national language, parental
level of education, number of working
hours per week, country of origin and
home-ownership) influenced the
change in IOD (dependent variable).
Potential confounding was corrected
for in a multivariable linear regression
analysis. Variable selection using a
stepwise backward approach with a p-
value cut-off of 0.20 was performed.
All statistical tests were two-sided with
a significance level of 0.05. Missing
data were minimal, the variable ‘com-
pliance’ had five missing data points,




Of the original cohort of 303 subjects,
208 were contacted successfully, 59
refused, 14 were excluded and we were
unable to examine one subject. We
included 134 (Fig. 1). Mean age at start
of therapy was 4.7 (2.0) years, 6.4
(2.1) years at end of therapy and 18.3
(2.1) years at follow-up examination.
Subjects who completed the follow-
up examination and those who did not
were comparable for the different base-
line characteristics (p > 0.05), except
for gender. The follow-up group had
significantly more females (p = 0.006;
44% in the original cohort versus 53%
in the follow-up group). Median com-
pliance and interquartile range (IQR)
in the original cohort (N = 303) was
71% (IQR 37–91) with 150 (50%)
subjects in the intervention group.
Median compliance in the follow-up
group (N = 134) was 73% (IQR 42–91)




89 (29%) unable to contact
6 (2%) moved abroad
134 (44%) included
59 (19%) refused re-examination
1 unable to examine
14 (5%) excluded
Fig. 1. Recruitment procedure for re-examination.
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intervention group. In 18 subjects,
compliance was lower than 20%.
Thirty-three subjects had strabismus
amblyopia, 75 anisometropic ambly-
opia, 21 had a combined cause of
amblyopia and 5 had deprivation
amblyopia. Retinal fixation was deter-
mined as central in 124 subjects and as
eccentric in 10 subjects.
Interocular visual acuity difference
Mean IOD at the start of treatment
was 0.27 (0.25) logMAR and 0.11
(0.16) logMAR at end of therapy.
Mean IOD at follow-up examination
was 0.09 (0.21) logMAR. There were
6 subjects who were prescribed occlu-
sion treatment after their last examina-
tion, but failed to show up for their
follow-up appointments. Patching
might have continued, but this could
not be confirmed. There was no signif-
icant difference between mean IOD at
end of therapy and at follow-up exam-
ination (N = 134; p = 0.054). In 63
(47%) subjects, the IOD had
decreased, that is less amblyopia; in
36 (27%) subjects it remained stable.
The IOD had increased, that is more
amblyopia, in 35 subjects: 14 of the 75
(19%) anisometropic, 8 of the 33
(24%) strabismic, 10 of the 21 (48%)
combined subjects and 3 of the 5 (60%)
subjects with deprivation amblyopia.
Subjects were categorized based on the
initial depth of amblyopia according to
the PEDIG criteria (Holmes et al.
2003; Repka et al. 2003). Figure 2
shows the course of the IOD for each
category. Subjects with severe ambly-
opia had improved most during occlu-
sion therapy, but had deteriorated the
most during follow-up examination.
Factors influencing the course of IOD
Univariable analysis showed that a
large IOD and high anisometropia at
start of occlusion therapy were both
associated with an IOD increase after
cessation of therapy. Eccentric fixation
and non-compliance during occlusion
therapy were also significantly associ-
ated with IOD increase. Results of the
univariable and multivariable analyses
are listed in Table 1.
Multivariable analysis showed that a
large IOD at start of occlusion therapy,
eccentric fixation at start of therapy
and an increasing anisometropia were
associated with IOD increase after
cessation of treatment. Of the socio-
economic variables, only parental level
of education was borderline significant
(p = 0.054) in the multivariable analy-
sis.
Increasing anisometropia and spectacle
wearing
It has been suggested by Simonsz-Toth
that amblyopia in children with
increasing anisohypermetropia is more
likely to deteriorate as new spectacles
are needed frequently to keep up with
the changing refractive error (Simonsz-
Toth et al. 2007). Overall, the degree of
anisometropia was stable or had
decreased (N = 91; 68%) with 0.09
(1.0) dioptres (D): 0.90D (1.0) at
start of occlusion therapy and 0.80D
(1.2) at the follow-up examination.
Eleven (8%) of the 35 subjects in whom
IOD had increased, also had an
increase of their anisometropia. In the
multivariable analysis (Table 1), an
increase in anisometropia was signifi-
cantly associated with an IOD increase
after cessation of therapy (p = 0.009).
To determine whether this association
could be explained by spectacle wear-
ing, we inquired about spectacle
wearing in daily life in all 134 subjects
and divided them into three categories.
Sixty subjects (45%) wore their specta-
cles at least more than 50% of all
waking hours; 20 (15%) wore specta-
cles <50% and 54 (40%) never wore
spectacle correction or did not have
any. Using univariable regression, a
relationship could not be demonstrated
(p = 0.064). Of the 54 subjects who
never wore spectacles or did not have
any, 17 showed an improvement with
additional correction. Interestingly, of
the 11 subjects who had an IOD
increase as well as an increase in
anisometropia, 6 seldom or never wore
spectacles.
Compliance
Mean compliance with occlusion ther-
apy as measured electronically was not
significantly associated with a change
in IOD (B = 0.000; p = 0.575). How-
ever, when comparing subjects who did
not comply with therapy at all (i.e.
compliance less than 20%) with sub-
jects with compliance more than 20%,
the non-compliers were at risk for IOD
deterioration after therapy (p = 0.028)
in the univariable analysis. This cut-off









Mild (N = 71)
Moderate (N = 46)









Fig. 2. Mean Interocular Visual Acuity difference between the amblyopic eye and fellow eye at
three points in time with 95% confidence intervals: at the start of occlusion therapy, at end of
therapy and at the follow-up examination 12–15 years later. Subjects are categorized, based on the
visual acuity of the amblyopic eye at start of occlusion therapy: mild (≤0.2 logMAR), moderate
(0.30–0.60 logMAR) and severe (0.70–1.3 logMAR).
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point of 20% was chosen as the lowest
point in the bimodal distribution of
compliance, which separated the chil-
dren who had not been occluded reg-
ularly or not at all from the children
who occluded routinely (Loudon et al.
2009). These non-compliers had a
mean IOD of 0.33 (0.33) logMAR
at start of therapy; 0.15 (0.27) at end
of their occlusion therapy and 0.23
(0.32) at follow-up examination. The
VA in the amblyopic eye increased
even with little patching, but deterio-
rated after therapy: 0.42 (0.33) log-
MAR at start, 0.21 (0.29) logMAR at
end of occlusion therapy and 0.14
(0.32) logMAR at follow-up
examination. Interestingly, of the 18
subjects with compliance less than
20%, 17 were in the control group; 1
in the intervention group who received
the educational cartoon programme.
The educational programme greatly
reduced the number of non-compliers
in the original study and significantly
improved the rate of VA increase
(Tjiam et al. 2012).
Subjects with severe visual acuity
deterioration after cessation of therapy
Of all 134 included subjects, five (4%)
had visual acuity deterioration in the
amblyopic eye of ≥0.2 logMAR lines
(Fig. 3); visual acuity in the fellow eye
was ≤0.0 logMAR. These five subjects
all had a combination of microstrabis-
mus, eccentric fixation and poor visual
acuity of the amblyopic eye at start of
occlusion therapy. In the first subject,
the amblyopia was caused by ani-
sometropia and strabismus; ani-
sometropia was 3.50D and had not
increased. Compliance with therapy at
the time was 59%. In the second
subject, the amblyopia was also caused
by anisometropia and strabismus; ani-
sometropia was 4.38 D and increased
with 1.4 D, he ceased wearing his
spectacles at age 12. Compliance was
0%. The third subject had a strabismus
Table 1. Results of the univariable and multivariable analyses: the influence of clinical and socio-economic variables on the change in IOD between
end of occlusion therapy and follow-up examination.
Independent variables
Univariable analysis Multivariable analysis
B 95% CI p-Value B 95% CI p-Value
Age at start of therapy (years) 0.016 0.032, 0.000 0.055
Gender**
Boys 0.022 0.044, 0.088 0.515 0.058 0.007, 0.108 0.026
Girls Reference
IOD at start of therapy (logMAR)** 0.235 0.106, 0.363 <0.001 0.332 0.205, 0.458 <0.001
IOD at end of therapy (logMAR)** 0.357 0.557, 0.157 0.001 0.647 0.820, 0.473 <0.001
Anisometropia at start of therapy (D)* 0.042 0.011, 0.073 0.008 0.020 0.009, 0.049 0.169
Diagnosis 0.052
Strabismus 0.110 0.290, 0.070 0.227
Anisometropia 0.150 0.323, 0.023 0.090
Combined 0.037 0.223, 0.150 0.698
Deprivation Reference
Eccentric fixation** 0.279 0.163, 0.396 <0.001 0.220 0.121, 0.319 <0.001
Compliance (%) 0.000 0.001, 0.001 0.575
Duration of occlusion therapy (years) 0.011 0.028, 0.049 0.579
Change in anisometropia (D)** 0.025 0.009, 0.059 0.155 0.037 0.009, 0.064 0.009
Intervention (educational programme) 0.045 0.021, 0.111 0.177
Parental fluency national language 0.618
Excellent 0.040 0.045, 0.126 0.353
Good 0.017 0.142, 0.107 0.782
Moderate 0.003 0.115, 0.110 0.964
Poor 0.076 0.060, 0.211 0.270
None Reference
Highest level of education 0.118 0.054
University 0.069 0.096, 0.234 0.406 0.003 0.120, 0.127 0.957
Higher education 0.094 0.061, 0.250 0.233 0.033 0.152, 0.085 0.580
Secondary education 0.163 0.006, 0.320 0.041 0.051 0.068, 0.169 0.398
Primary education 0.061 0.098, 0.219 0.452 0.051 0.172, 0.069 0.401
None Reference
Number of working hours per week 0.000 0.003, 0.002 0.732
Country of origin 0.131
Natives 0.048 0.039, 0.135 0.275
Surinam 0.028 0.102, 0.157 0.673
Morocco 0.063 0.045, 0.171 0.250
Turkey 0.074 0.186. 0.037 0.188
Other Reference
Home-ownership
Yes 0.031 0.099, 0.038 0.379
No Reference
* Variable significantly affecting change in IOD after univariable analysis (p < 0.05).
** Variable significantly affecting change in IOD after multivariable analysis (p < 0.05).
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amblyopia; anisometropia was 0.25 D
and increased with 0.50 D. She has
never worn any refractive correction.
Compliance was 99%. The fourth sub-
ject had strabismus and anisometropia
amblyopia; anisometropia was 1.0 D
and increased with 5 D, she did not
wear adequate spectacle correction.
Compliance was 98%. The fifth subject
had strabismus and anisometropia
amblyopia; anisometropia was 1 D
and had not increased. Compliance
was 0% at the time. He wore adequate
spectacle correction.
Binocular vision
In 34 (25%) subjects, binocular vision
at end of therapy was unknown and
therefore, a comparison could not be
made. Suppression as measured by
Bagolini striated glasses was stable in
the majority of the subjects (N = 95;
71%). Three subjects scored a positive
Bagolini test at end of therapy, but
showed suppression on the Bagolini
test at follow-up of whom two also
showed profound deterioration in
visual acuity of the amblyopic eye.
Figure 4 shows the change in binocular
vision of the 100 subjects at end of
therapy and at the time of the follow-
up examination; this change was not
statistically significant (p = 0.406).
Reading acuity
The mean reading acuity for the ambly-
opic eye was 0.19  0.26 logMAR and
0.05  0.14 logMAR for the fellow
eye. Visual acuity at start of treatment
was positively significantly correlated
(Spearman correlation 0.377;
p < 0.001) with reading acuity at fol-
low-up. Visual acuity at follow-up and
reading acuity at follow-up were also
significantly correlated (Spearman cor-
relation 0.680; p < 0.001).
Discussion
This study evaluated the long-term
outcome of visual acuity in subjects
who received occlusion therapy for
amblyopia 12–15 years ago (Loudon
et al. 2006). Visual acuity was mea-
sured under strictly controlled circum-
stances by the same orthoptist at end of
therapy and at the long-term follow-
up. Overall, we found good long-term
results of occlusion therapy: 74% had
stable or improved IOD.
Risk factors for IOD increase
included degree of anisometropia,
increasing anisometropia, eccentric fix-
ation and non-compliance during
occlusion therapy. A large IOD at the
start of occlusion therapy was also
significantly correlated with IOD
increase after cessation of therapy.
However, subjects with low initial VA
also had worse compliance (Loudon
et al. 2006) with patch wearing, but
increased the most during therapy even
with little patching. Subjects who
increased the most during occlusion
therapy were the most at risk for loss of
logMAR lines after cessation of ther-
apy explaining the found association
between compliance and IOD increase
after therapy.
Out of five subjects with severe
deterioration (i.e. ≥2 logMAR lines)
after cessation of occlusion therapy,
four had a combined cause of ambly-
opia; three had increasing ani-
sometropia and also had not worn
their spectacles. One study comparable
to ours was conducted by Simonsz-
Toth (N = 137), who found 18 subjects
(13%) with profound deterioration
(>50% loss in visual acuity) in visual
acuity 30 years after finishing occlusion
treatment; 15 (11%) of these had an
increase of anisometropia (Simonsz-
Toth et al. 2007). In that study, the
orthoptist who had examined the sub-
jects during occlusion therapy also
took part in the follow-up evaluation.


















Fig. 3. InterOcular VA Difference of the five subjects (number 1–5) with the largest VA
deterioration measured at start of occlusion therapy, end of therapy and at follow-up
examination. Four had a combined cause of amblyopia.
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Fig. 4. Binocular vision of the subjects at end of occlusion therapy and at the time of the follow-
up examination. The degree of binocular vision was arranged into five categories: 1. Bagolini




In our study, we found a lower per-
centage with severe visual acuity dete-
rioration. This difference could be
attributed to differences in length of
follow-up time or improved spectacle
wearing nowadays. We asked the sub-
jects whether they had worn their
spectacles, but on the basis of these
data no statistically significant relation-
ship was found.
Possible bias could be introduced to
the analysis because of the 51% who
either refused or could not be con-
tacted. However, the statistical analysis
showed that, except for gender, the
subjects included for this study were a
representative sample. We had more
girls, maybe due to the fact that girls
are more motivated to participate in a
study. We also had missing data
regarding the binocular vision, which
could lead to a possible bias.
Another limitation in our study was
that cycloplegic refraction was not
performed. Our initial proposal did
include cycloplegic refraction, but this
was refused by most of the subjects.
For calculation of the absolute refrac-
tive error, subjective refraction may not
be ideal. However, for calculating the
difference in refractive error between
the eyes, that is the degree of ani-
sometropia, it is expected that using
subjective refraction is reliable. This is
relevant as the degree of anisometropia
and increasing anisometropia showed
to be significantly correlated with IOD
increase after cessation of occlusion
therapy.
The Landolt-C 17.2” chart does not
fulfil all the criteria of a ‘crowded’
chart and therefore, visual acuity in the
amblyopic eye may be over-scored. As
primary outcome measure in the study,
we used visual acuity measured as
much as possible according to ISO-
8596 Standard. The measurement of
visual acuity with crowded optotypes is
especially needed in the diagnosis and
treatment of amblyopia, not so much
in the final evaluation of the result of
therapy. As we aimed to have compa-
rable testing conditions for the follow-
up measurements, we preferred to use
the same chart as in 2004 and mea-
surements were performed by the same
orthoptist (BST).
Finally, it cannot be ruled out that
there are other unknown factors that
could cause changes in visual acuity as
children grow older. Therefore, as a
measure for amblyopia, we used IOD
as this would avoid part of the vari-
ability of the VA measurement.
We conclude that long-term results
of occlusion therapy as a treatment for
amblyopia were successful. High or
increasing anisometropia, eccentric fix-
ation and non-compliance during
occlusion therapy were associated with
increasing IOD and hence, with long-
term visual acuity decrease.
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